Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 204

1.

Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness.

Kennedy SH, Rizvi SJ.

CNS Drugs. 2010 Jun;24(6):479-99. doi: 10.2165/11534420-000000000-00000. Review.

PMID:
20192279
2.

Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action.

Kasper S, Hamon M.

World J Biol Psychiatry. 2009;10(2):117-26. doi: 10.1080/15622970902717024. Review.

PMID:
19255935
3.

Treating each and every depressed patient.

Kennedy SH.

J Psychopharmacol. 2008 Sep;22(7 Suppl):19-23. doi: 10.1177/0269881108093270. Review.

PMID:
18753279
4.

Agomelatine, a melatonin agonist with antidepressant properties.

Dubovsky SL, Warren C.

Expert Opin Investig Drugs. 2009 Oct;18(10):1533-40. doi: 10.1517/13543780903292634. Review.

PMID:
19758108
5.

The emerging role of melatonin agonists in the treatment of major depression: focus on agomelatine.

De Berardis D, Di Iorio G, Acciavatti T, Conti C, Serroni N, Olivieri L, Cavuto M, Martinotti G, Janiri L, Moschetta FS, Conti P, Di Giannantonio M.

CNS Neurol Disord Drug Targets. 2011 Feb;10(1):119-32. Review.

PMID:
20874703
6.

Agomelatine: efficacy at each phase of antidepressant treatment.

Kennedy SH.

CNS Drugs. 2009;23 Suppl 2:41-7. doi: 10.2165/11318660-000000000-00000. Review.

PMID:
19708725
7.

Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study.

Hale A, Corral RM, Mencacci C, Ruiz JS, Severo CA, Gentil V.

Int Clin Psychopharmacol. 2010 Nov;25(6):305-14. doi: 10.1097/YIC.0b013e32833a86aa.

PMID:
20856123
8.

Addressing circadian rhythm disturbances in depressed patients.

Lam RW.

J Psychopharmacol. 2008 Sep;22(7 Suppl):13-8. doi: 10.1177/0269881108092591. Review.

PMID:
18753278
9.

Efficacy and tolerance profile of agomelatine and practical use in depressed patients.

Rouillon F.

Int Clin Psychopharmacol. 2006 Feb;21 Suppl 1:S31-5.

PMID:
16436938
10.

Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline.

Kasper S, Hajak G, Wulff K, Hoogendijk WJ, Montejo AL, Smeraldi E, Rybakowski JK, Quera-Salva MA, Wirz-Justice AM, Picarel-Blanchot F, Baylé FJ.

J Clin Psychiatry. 2010 Feb;71(2):109-20. doi: 10.4088/JCP.09m05347blu.

PMID:
20193645
11.

Agomelatine: a novel pharmacological approach to treating depression.

Owen RT.

Drugs Today (Barc). 2009 Aug;45(8):599-608. doi: 1396673/dot.2009.45.8.1396673. Review.

PMID:
19927226
12.
13.

The effect of melatonergic and non-melatonergic antidepressants on sleep: weighing the alternatives.

Pandi-Perumal SR, Trakht I, Srinivasan V, Spence DW, Poeggeler B, Hardeland R, Cardinali DP.

World J Biol Psychiatry. 2009;10(4 Pt 2):342-54. doi: 10.1080/15622970701625600. Review.

PMID:
18609422
14.

Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study.

Stein DJ, Ahokas AA, de Bodinat C.

J Clin Psychopharmacol. 2008 Oct;28(5):561-6. doi: 10.1097/JCP.0b013e318184ff5b.

PMID:
18794654
15.

The importance of early symptom relief in antidepressant treatment: focus on agomelatine.

Lam RW.

J Psychopharmacol. 2010 Aug;24(2 Suppl):27-30. doi: 10.1177/1359786810372979. Review.

PMID:
20663806
16.

The antidepressant agomelatine improves the quality of life of depressed patients: implications for remission.

Llorca PM.

J Psychopharmacol. 2010 Aug;24(2 Suppl):21-6. doi: 10.1177/1359786810372978. Review.

PMID:
20663805
17.

Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial.

Goodwin GM, Emsley R, Rembry S, Rouillon F; Agomelatine Study Group.

J Clin Psychiatry. 2009 Aug;70(8):1128-37. doi: 10.4088/JCP.08m04548. Epub 2009 Aug 11.

PMID:
19689920
18.

Major depressive disorder, anhedonia and agomelatine: an open-label study.

Di Giannantonio M, Di Iorio G, Guglielmo R, De Berardis D, Conti CM, Acciavatti T, Cornelio M, Martinotti G.

J Biol Regul Homeost Agents. 2011 Jan-Mar;25(1):109-14.

PMID:
21382280
19.

Agomelatine: innovative pharmacological approach in depression.

Popoli M.

CNS Drugs. 2009;23 Suppl 2:27-34. doi: 10.2165/11318640-000000000-00000. Review.

PMID:
19708723
20.

Melatonin receptor agonist agomelatine: a new drug for treating unipolar depression.

Bourin M, Prica C.

Curr Pharm Des. 2009;15(14):1675-82. Review.

PMID:
19442180
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk